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Long-term pantethine treatment counteracts pathologic gene dysregulation 
and decreases Alzheimer’s disease pathogenesis in a transgenic mouse 
model. 
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Abstract 
Background: The low-molecular weight thiol pantethine, known as a hypolipidemic and 
hypocholesterolemic agent, is the major precursor of co-enzyme A. We have previously 
shown that pantethine treatment reduces amyloid- (A)-induced IL-1 release and alleviates 
pathological metabolic changes in primary astrocyte cultures. These properties of pantethine 
prompted us to investigate its potential benefits in vivo in the 5XFAD (Tg) mouse model of 
Alzheimer’s disease (AD).  
Methods: 1.5-month-old Tg and wild type (WT) male mice were submitted to intraperitoneal 
administration of pantethine or saline control solution for 5.5 months. The effects of such 
treatments were investigated by performing behavioral tests and evaluating astrogliosis, 
microgliosis,  deposition and whole genome expression arrays, using RNAs extracted from 
the mice hippocampi. 
Results: We observed that long-term pantethine treatment significantly reduced glial 
reactivity and  deposition, and abrogated behavioral alteration in Tg mice. Moreover, the 
transcriptomic profiles revealed that after pantethine treatment, the expression of genes 
differentially expressed in Tg mice, and in particular those known to be related to AD, were 
significantly alleviated. Most of the genes overexpressed in Tg compared to WT were 
involved in inflammation, complement activation and phagocytosis, were found repressed 
upon pantethine treatment. In contrast, pantethine restored the expression of a significant 
number of genes involved in the regulation of  processing and synaptic activities, which 
were down-regulated in Tg mice.  
Conclusions: Altogether, our data support a beneficial role for long-term pantethine treatment 
in preserving CNS crucial functions altered by A pathogenesis in Tg mice, and highlight the 
potential efficiency of pantethine to alleviate AD pathology.  
 
Keywords: Alzheimer’disease, pantethine, gene expression profiles, neuroprotection, 
phagocytosis, 5xFAD mice 
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Background 
Alzheimer’s disease (AD) is the most common cause of dementia worldwide. It is 
characterized by a progressive cognitive impairment thought to be associated with the 
accumulation of extracellular amyloid plaques, composed of amyloid- peptide (A) and 
intracellular neurofibrillary tangles (NFTs). NFTs result from an alteration of microtubule 
stabilization following the abnormal hyperphosphorylation of Tau, a microtubule-associated 
protein. The production of A is triggered by a successive proteolytic cleavage of the -
amyloid precursor protein (APP) by the -secretase, BACE-1 (beta-site APP cleaving enzyme 
1) and the -secretase complex. Among the different A peptides generated from APP, A42 
is believed to play a primary role in the development of AD (1). The deposition of 
extracellular A is associated with a neuroinflammatory response and it is suggested that 
upon sustained A production, the resulting chronic inflammation contributes to AD 
pathology (2, 3). Therapeutic strategies based on the reduction of Tau hyperphosphorylation 
or A are under evaluation in addition to those developed to improve cognitive function 
(acetylcholinesterase inhibitors) and mood disturbance or to provide neuroprotection 
(memantine). However, to date, available treatments show only modest symptomatic effects. 
Moreover, epidemiological studies have suggested that longstanding use of anti-inflammatory 
drugs such as NSAIDs (non-steroidal anti-inflammatory drugs) can prevent or delay the 
development of AD (4, 5). Unfortunately, treatment of AD patients with anti-inflammatory 
drugs such as celecoxib or naproxen failed to demonstrate clinical benefits (6, 7). These 
failures illustrate our poor understanding of the sequential events of neuroinflammation in AD 
that, depending possibly on timing and context, can either promote protective effects or 
exacerbate the disease (8). Thus, in addition to their potential therapeutic efficacy, search for 
new modulators of inflammation can be useful in determining whether inflammation is a 
driving force or a bystander effect in AD. 
Pantethine, a dietary low-molecular-weight thiol widely distributed in the living world and 
synthesized from pantothenic acid (vitamin B5) and cysteamine, is an intermediate in the 
production of Co-enzyme A (CoA). This activity is thought to be related to its well-known 
effect on lowering cholesterol synthesis (9). However, pantethine can be rapidly hydrolyzed 
in vivo to pantothenic acid and cysteamine by pantetheinase encoded by the vanin gene, and it 
cannot be excluded that its observed activities might result from cysteamine or pantothenic 
acid (10, 11). Pantethine elicits broad physiological activities involving multiple cellular 
pathways. It has been shown to exert neuroprotective effects and to reduce metabolic 
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dysfunctions (12-14), but also to decrease inflammation and mediate immune responses (15, 
16). We have previously shown that pantethine is able to protect mice against cerebral malaria 
by preserving blood brain barrier integrity and by lowering TNF- levels (16). More recently, 
we demonstrated that pantethine alleviates metabolic dysfunctions, reduces astrogliosis and 
IL-1 production in primary cultured astrocytes of 5XFAD mice (17). Such beneficial effects 
were also observed in WT astrocytes treated with A oligomers. These data suggest that 
pantethine could help maintain brain homeostasis and function during AD pathogenesis.  
Such observations prompted us to explore pantethine activity in vivo using 5XFAD mice. This 
animal model bears five mutations linked to familial forms of AD and recapitulates in a few 
months the main features of AD. These mutations act in an additive manner to boost the 
production of Aβ peptides, particularly Aβ42. Though they do not present tau pathology, these 
mice develop cerebral amyloid plaques and gliosis as early as two months (18), along with 
increased levels of pro-inflammatory mediators Il-1 and Ccl2 mRNAs (19). 
Electrophysiological studies have detected hippocampal synaptic dysfunctions in 4- to 6-
month-old 5XFAD animals, concomitant with memory deficits (18, 20-25). Neuronal death, 
which is absent in most AD mouse models, has been described in the cortex and subiculum in 
9-month-old 5XFAD mice (18, 26). In a previous longitudinal transcriptomic study, we 
showed that the main processes altered in 5xFAD mice, from 4 months onwards, were related 
to microglial activation and inflammation (27).  
To investigate the effects of pantethine on AD pathology, 1.5 month-old 5xFAD transgenic 
(Tg thereafter) and wild type (WT thereafter) mice were treated with pantethine for 5.5 
months (see materials and methods). In line with our previous data (17), a significant decrease 
in gliosis and A plaque deposits was observed in treated Tg mice compared to untreated. 
Treatment also improved behavior with a significant decrease of aggressiveness. 
Transcriptomic analyses showed that pantethine was indeed able to tune down the 
modulations in gene expression characteristic of the Tg mice. We present for the first time an 
array of evidences supporting a beneficial effect of pantethine in AD. Thus, its current use 
and the possibility of chronic treatment in the absence of known side effects provide the 
grounds to test the efficacy of pantethine in AD as a new therapeutic agent in preclinical and 
clinical studies.  
 6 
Materials and methods 
 
Chemical 
Pantethine was purchased from Sigma-Aldrich (Saint Quentin-Fallavier, France). Purity of the 
preparation was ascertained using high performance liquid chromatography-coupled mass 
spectrometry (HPLC-LC-UV-MSD) and the purity of the compound reached 99%. Sodium 
Chloride (NaCl) and Phosphate Buffer Saline (PBS) were purchased from Euromedex 
(Souffelweyersheim, France). Proteinase inhibitors cocktail was from Millipore (Molsheim, 
France). All the chemical powders were of analytical grade and purchased from Sigma-
Aldrich. 
 
Animals and pantethine treatment 
We used 5XFAD male transgenic mice, which overexpress two human transgenes bearing 
five mutations linked to familial AD: App (Swedish mutation K670N, M671L; Florida 
mutation I716V; London mutation V717I) and Psen1 (M146L; L286V), under transcriptional 
control of the mouse Thy1 promoter. These mice exhibit AD-related symptoms earlier than 
other AD animal models and amyloid deposition starts in the cortex and subiculum at two 
months of age (18). Heterozygous male 5XFAD transgenic animals (B6/SJL background) and 
WT controls were obtained after breeding in our animal house facility (19, 27, 28). 
Animals were housed in cages in a controlled environment (22-25°C, 50% humidity and a 12-
hour light/dark cycle) with free access to standard laboratory diet and water. At 1.5 month, Tg 
and WT mice were each separated into treated and vehicle groups (n=10 per group). Based on 
a previous study (13), Tg and WT treated mice were given each an intraperitoneal injection of 
15 mg of pantethine diluted in saline, three times a week for 5.5 months; vehicle animals 
received saline injections as control. At the age of 7 months, the animals were submitted to 
the intrudal aggressivity test (see below) and then sacrificed. Mice were anesthetized with 
pentobarbital (0.36 g per kg) and transcardially perfused with 50 ml of NaCl 0.9%. Brains 
were microdissected and hippocampi collected for the assays. All experimental procedures 
were approved by the Ethics Committee of the Medical Faculty of Marseille and were carried 
out in accordance with the guidelines published in the European Communities Council 
Directive of November 24, 1986 (86/609/EEC). All efforts were made to reduce animal 
suffering and the number of mice. 
 
Total RNA isolation and extraction 
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Hippocampi from each experimental group (n=3 per group) were quickly snap-frozen in 
liquid nitrogen and stored at -80°C until use. Total RNA was extracted using the RNeasy 
Mini kit (Qiagen, Courtaboeuf, France) according to the manufacturer’s instruction. RNA 
concentration was determined using a nanodrop 2000 spectrophotometer (ThermoFisher 
Scientific, Villebon sur Yvette, France) and RNA integrity assessed on an Agilent 2100 
Bioanalyzer (Agilent Technologies, Les Ulis, France). 
 
Microarray assay 
The microarray assay included four different experimental conditions: hippocampi from WT 
and Tg mice vehicle or treated with pantethine (n=3 per group). A total of 12 biological 
samples were therefore processed for the microarray experiment. The mouse WG-6 
expression BeadChip (Illumina Inc., Cambridge, UK), comprising 47,232 transcripts was 
used to generate gene expression profiles and hybridized to cRNAs, which were synthesized, 
amplified and purified using the Illumina TotalPrep RNA Amplification Kit (Ambion, Foster 
City, CA, USA) following manufacturer’s recommendations. Briefly, 200 ng of RNA were 
reverse transcribed. After second strand synthesis, the cDNA was transcribed in vitro and 
cRNA labelled with biotin-16-UTP. Labelled probe hybridization to the Beadchips was 
carried out using Illumina’s protocol. The Beadchips were scanned on the Illumina IScan 
using Illumina IScan image data acquisition software. Illumina GenomeStudio software and 
LumiR (www.bioconductor.org) were used for preliminary data analysis, data normalization 
and quality controls. Microarray statistical analyses were performed using the Biometric 
Research Branch array tools (http://linus.nci.nih.gov/BRB-Array Tools.html) and the Multi 
Experiment Viewer software (MeV4.0; (29)). Expression values were filtered for a p value ≤ 
0.05. Functional analysis was performed using the text-mining based software, PredictSearch 
(27). Microarray data are available in the Array Express database 
[www.ebi.ac.uk/arrayexpress] under accession number E-MTAB-6772. 
 
Real-time quantitative PCR (qPCR) 
Following microarray analysis, the expression levels of some selected genes were further 
validated using qPCR technique. Total RNA samples (1 μg) extracted from the hippocampi of 
all animals (n=3) in each group were subjected to reverse-transcription reactions to synthesize 
cDNA using oligodT, RNase–out and M-MLV RT enzyme (ThermoFisher Scientific) 
according to the manufacturer’s instructions. Two genes, Gfap and Aif1, related to astrocytic 
and microglial activation, respectively, were selected for pre-validation of samples, and one 
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housekeeping gene, Gapdh, was used for sample normalization. Real-time qPCR experiments 
were carried out with the 7500 Fast Real-Time PCR system (Applied Biosystems, Thermo 
Fisher Scientific), using TaqMan Fast Universal PCR Laster Mix (2X) and the following 
TaqMan Gene Expression probes were used: Gfap, Mm01253033_m1; Aif1, 
Mm00479862_g1; Il-1, Mm01336199_m1; Csf1r, Mm01266652_m1; Tlr2, 
Mm01213946_g1; Cyba, Mm00514478_m1; Tnf-, Mm00443258_m1 and Gapdh, 
Mm99999915_g1. We used 7.5 ng of previously prepared cDNA and samples were run in 
triplicates. Relative expression levels were determined according to the Ct method where 
the expression level of the mRNA of interest is given by 2
-CT
 where CT = CT target 
mRNA – CT reference mRNA (Gapdh) in the same sample (19).  
 
ELISA assay 
The cortices of mice brains (n=3 for each condition) were homogenized in 100 mM PBS 
containing 2 mM NaF, 2.5 mM Na4P2O7, 1 mM Na3VO4, 1% Triton X-100, pH 7.2, 
supplemented with 1% protease inhibitor cocktail and centrifuged at 12,000 x g for 20 min at 
4°C. Protein concentration was quantified by using the Bio-Rad DC™ protein assay kit 
following the manufacturer's instructions (Bio-Rad, Marnes-La-Coquette, France). The levels 
of IL-1β were analyzed by ELISA assay (Peprotech, Neuilly-sur-Seine, France) according to 
the manufacturer's instructions.  
 
Immunostaining, image analysis and quantification 
Anesthetized mice were transcardially perfused with 50 ml of NaCl 0.9%, followed by 50 ml 
of AntigenFix solution (Diapath, MM France, Brignais, France). Coronal sections of 30 μm 
were obtained using a vibratome (Microm HM650V, Thermo Fisher Scientific), and stored at 
-20°C in cryoprotectant containing 30% glycerol, 30% ethylene glycol and 40% in phosphate 
buffer 0.5 M, pH 7.4. Free-floating sections were first permeabilized and blocked for 1 h at 
room temperature using a solution of PBS 1X, 0.1% Triton X-100 and 3% BSA. Sections 
were then incubated overnight at 4°C with primary antibodies: mouse monoclonal anti-Aβ 
6E10 (1/300; Covance, Ozyme, Saint-Quentin en Yvelines, France), rabbit polyclonal anti-
IBA1 (1/300; Wako, Sobioda, Montbonnot, France), Rabbit polyclonal anti-GFAP (1/300, 
Dakocytomation, France) followed by an incubation with appropriate secondary antibodies: 
AlexaFluor488-goat anti-rabbit (1/800) or AlexaFluor568-goat anti-mouse (1/800) 
(Thermo Fisher Scientific) for 1 h at room temperature. Nuclei were stained with Hoechst (0.5 
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µg/mL, Thermo Fisher Scientific). Omission of the primary antibody was used as control. 
Sections were mounted using Prolong Gold Antifading reagent on Superfrost glass slides 
(Thermo Fisher Scientific). Images were taken and processed using a confocal microscope 
(LSM700) and Zen software (Zeiss, Jena, Germany), as previously described (24, 30). 
Densitometric analysis of immunostained sections was performed using ImageJ software on 3 
hippocampal sections from 3 animals for each experimental group. The area of GFAP
+
 
astrocytes and IBA1
+
 microglia was determined. The same threshold of fluorescence was 
applied across the experimental groups and data were normalized to the values in the WT 
group. Extracellular amyloid deposits were blindly scored in the three brain sections per 
animal and expressed as number of plaques per mm
2
 of brain surface. 
 
Intrudal aggressivity test 
The effect of pantethine on Tg male mice aggressiveness was evaluated with the resident-
intruder paradigm according to a previously published method (31), and modified according 
to our experimental situation. The animals to be tested, treated or not with pantethine (n=10 
per group) were maintained in their individual resident cage in order to mimic the natural 
pattern of wild animals that defend their territory. The intruders were WT male mice (n=10) 
from the same genetic background, but not included in this protocol. For the test, a WT 
animal was introduced in the cage of a Tg and their behavior were monitored with a video 
camera for 180 sec. The following behavioral elements were scored: 1) latency: the time 
between the introduction of the intruder and the first threat or attack; 2) number of threats that 
are generally in the form of frenetic tail agitation; 3) number of assaults. Threats and assaults 
were exclusively facts of the Tg resident as the WT intruder always behaved passively. In the 
case of violent assault, the animals were immediately separated and the test ended. The 
offense intensity was estimated on a scale of 0 to 5. The latency time was set at 180 sec when 
no reaction, threat or attack was noticed. The tests were done 3 times on 3 consecutive days 
under normal light, starting at 10 am. From one test to another, the intruders were circularly 
permuted. Intrudal aggressivity experiments were performed at least three times for each 
animal.  
 
Statistical analysis 
All the data were analyzed with Kaleida Graph or Prism softwares and the values represent 
the means +/- SEM of the indicated number of independent experiments/animals. ANOVA 
followed by a Fisher’s LSD post-hoc test was used for multiple comparisons. For the 
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aggressiveness analysis we used a non-parametric Mann-Whitney test and results are 
represented as median and interquartile range. Only p values less than 0.05 were considered 
significant. The p levels p<0.05, p<0.01 and p<0.001 are denoted with asterisks *, ** and 
***, respectively.  
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Results  
Pantethine reduces gliosis and amyloid plaque number 
The 5XFAD mouse model of AD is characterized by an increase in glial reactivity and 
amyloid plaque number as aging progresses. At first, immunohistological analyses of brain 
sections at the hippocampal level in 7-month-old Tg and WT mice (Fig. 1A) supported our 
previous results on cultured astrocytes (17). Indeed, in sections immunostained with anti-
GFAP and anti-IBA1 antibodies, Tg mice consistently exhibited a higher signal (10-fold and 
20-fold increase, respectively) than WT mice (Fig. 1A, B). Pantethine treatment reduced this 
signal significantly in Tg animals, with an 80% and 40% reduction for GFAP and IBA1, 
respectively. Interestingly, pantethine reduced GFAP staining nearly to WT levels (Fig. 1B). 
Similarly, staining with A-specific antibodies showed that the numerous amyloid deposits 
observed in Tg mice were dramatically reduced by 85% upon pantethine treatment (Fig. 1C). 
These results indicated that pantethine was able to reduce significantly glial reactivity as well 
as the number of amyloid plaques in Tg mice.  
 
Pantethine reduces 5XFAD aggressive behavior  
AD pathology leads to cognitive impairment and behavioral alterations linked to amyloid-
mediated neuroinflammation and neurodegeneration. Although altered cognition has been 
well characterized in a variety of transgenic models, it has been reported that disturbance in 
hippocampal learning performance can be detected using the Morris water maze (MWM) in 
male 5XFAD not before 6 to 9 months of age (23, 32). Alternatively, social withdrawal and 
aggressiveness have been clearly documented not only in AD patients (33-35), but also in 
different AD mouse models (34, 36-38), and was proposed to be useful in screening putative 
drug treatments for AD (36). For these reasons, we chose to evaluate the potential benefit of 
pantethine on the behavior of 7 month-old AD mice rather than on cognitive performances. 
Thus, we performed an intrudal aggressive test with treated and untreated Tg mice in the 
presence of WT animals. When comparing untreated and treated 5XFAD mice (Fig. 2), we 
observed a significant difference between these two groups, not only in offense intensity (Fig. 
2A), but also in attack latency (Fig. 2B). Most (8 out of 10) vehicle-treated Tg animals react 
aggressively to the presence of WT mice, while only 4 out of 10 treated animals exhibit such 
a behavior (Fig. 2A). Moreover, pantethine treated animals present a longer latency period 
(150s) between the attacks (Fig. 2B), confirming that pantethine treatment is able to modulate 
the aggressive attitude of Tg mice. 
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Panthetine moderates the dysregulation of gene expression observed in 5XFAD mice  
cDNA microarrays were performed to investigate whether the reduced astroglial and 
microglial activation, as well as the positive impact on behavior observed after pantethine 
treatment, could be related to a modulation of the expression of genes involved in these 
processes. The selection of genes in Tg animals presenting a reduced expression upon 
pantethine treatment (filtered for a threshold ≤0.6) led to the identification of 47 specific 
genes (Fig. 3, left panel). Interestingly, 91% of these genes (gene set 1) were expressed at 
higher levels in Tg mice compared to WT. Similarly, 89% of the top 47 genes (gene set 2) up-
regulated in pantethine-treated Tg animals when compared to untreated Tg mice (filtered for a 
threshold ≥1.5), were down-regulated in Tg when compared to WT (Fig. 3, right panel). 
Noteworthy, pantethine had very little if no effect at all on the expression of most of these 
genes in WT animals (Fig. 3). It must be noted that none of the genes encoding proteins 
directly associated with the APP/A metabolism (e.g., Bace-1, App, or -secretase members) 
were modulated between vehicle and pantethine-treated Tg mice (data not shown). 
A similar tendency was confirmed when we analyzed the genes modulated in Tg mice after 
pantethine treatment in relation to all genes differentially expressed in Tg compared to WT 
(Fig. 4). Among the 154 genes down-regulated in Tg, 80% (124 genes) were up-regulated by 
pantethine in Tg while none were further repressed. On the other hand, out of the 362 genes 
whose expression was upregulated in Tg versus WT, only 43 genes (12%) showed a reduced 
expression upon pantethine treatment (Fig. 4). These observations suggested that pantethine 
was able to counteract the modulation of gene expression in 5XFAD mice and this inhibitory 
effect could account for the preservation by pantethine of physiological functions normally 
altered in these mice.  
 
Inhibitory effect of pantethine on the expression of 5XFAD dysregulated genes in 
inflammation and related activities 
At first, to investigate which processes could be targeted by pantethine, we focused our 
analysis on genes whose up-regulation was statistically significant in Tg compared to WT and 
that presented a lower expression in pantethine-treated Tg animals. A significant number of 
these genes (Table 1) were reported in our previous temporal gene profiling study (27) and 
are known to be related to glial activation and neuroinflammation in an AD context. Figure 5 
shows the relationships between these genes and related AD activities identified through a 
bibliographic search using PredictSearch software (27, 39). Indeed, most of these activities 
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highlight the role of the selected genes in astroglial activation (Gfap, S100a6), microglial 
activation (Aif1/Iba1, CD68, Hexb2) and phagocytosis (Cd14, Trem2, Tyrobp, Csf1r, C1qa, 
C1qb, C1qc, C4a, and C4b).  
Similarly to allograft inflammatory factor 1/Iba1 (AIF1), CD68 is considered a marker of 
phagocytic microglia. Cd63, encoding a marker of exosomes, and Lgals3 (galectin 3), were 
found to be co-expressed in 5XFAD mice in A plaque-associated microglia (40), cells that 
are considered as primary contributors to neuroinflammation in AD pathology.  
Furthermore, the reduced expression of Gfap, a marker of astroglial activation, suggested that 
the effects of pantethine were not restricted to microglia. Indeed, S100a6, that encodes a 
Ca
2+
/Zn
2+
 binding protein, was reported to be overexpressed in astrocytes of AD patients and 
AD mouse models (41). In contrast to astrocytes of white matter where all S100A6 proteins 
were expressed homogeneously, almost all S100A6 immunoreactive cells within the gray 
matter were concentrated in astrocytes surrounding the A deposits.  
Genes encoding TLR2, TLR7, and CD14 were upregulated in the cortex of distinct transgenic 
murine models of various neuroinflammatory diseases, including AD (42). It must be noted 
that the TLR-mediated microglial response has both beneficial roles in stimulating 
phagocytosis as well as detrimental roles in the Aβ-stimulated release of neurotoxic products 
(43). TLR2 is a known primary receptor for A peptide to trigger neuroinflammation (44, 45). 
Its co-receptor, CD14, is a critical regulator of the microglial inflammatory response that 
modulates A deposition (46).  
In addition to other inflammatory markers, complement activation products are known to be 
markedly upregulated in AD brains in response to soluble and insoluble amyloid peptides (47, 
48). Their activation, detected at the early stages of amyloid deposition, coincides with the 
clinical expression of AD (49, 50). The encoded products are components of both the 
alternative phagocytic pathway (AP), triggered by bacterial membranes, and the classical 
phagocytic pathway (CP), initiated when C1Q binds to immune complexes (48, 51, 52). The 
expression of these components in transgenic mice might also be considered as part of a 
protective response. For instance, C1Q was shown to protect cultured primary neurons against 
A (53), and C3 deficiency in AD transgenic mice was reported to elicit an acceleration of 
plaque deposition and neurodegeneration compared to WT (54).  
Other genes revealed by our analyses such as Csf1r, Trem2 and Tyrobp (Table 2) have been 
reported to be involved in phagocytosis (Fig. 5). In addition to the classical phagocytic 
receptors FCGR3 and CD68, CSF1R (colony stimulating factor 1 receptor) as well as CD14, 
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contribute to A phagocytosis (55, 56). In a recent report (57), the role of CSF1R was 
determined as being crucial for the accumulation of intraneuronal amyloid peptides and the 
consequent formation of neuritic plaques. Here, we confirmed that the expression of Csf1r 
was increased in Tg compared to WT and significantly decreased upon pantethine treatment 
(Table 2). Furthermore, pantethine reduced the expression of Trem2, which presented the 
highest fold change (10-fold) within the set of Tg overexpressed genes (Table 1), along with 
the gene encoding its interactor, Tyrobp. Trem2 is highly expressed in microglia and the 
Trem2/Tyrobp pathway activates phagocytosis of apoptotic neurons as well as A in cultured 
cells (58). While this pathway inhibits TLR-induced inflammation (59), it was reported that, 
in a mouse model of AD, Trem2 deficiency reduced pro-inflammatory cytokines (IL-1 and 
IL-6) as well as astrogliosis (60). According to this observation, in AD mice, the reduced 
expression of Trem2 in response to pantethine at a particular inflammatory stage might 
contribute to hamper the production of cytokines in Trem2 expressing cells.  
AIF1 binds to and polymerizes F-actin, and regulates RAC1 activity (61). RAC1 participates 
in the activation of the NADPH oxidase (NOX) complex leading to production of superoxide 
(Fig. 5). Among the genes encoding the different subunits of this complex, only the 
overexpression of Cyba in Tg (cytochrome b-245 alpha gene/p22phox) was drastically 
reduced in pantethine-treated Tg as shown in Table 1. CYBA is considered as a critical 
component of the membrane-bound oxidase of phagocytes that generates superoxide. A is 
known to act on NOX in both hippocampal microglial and astrocyte cells to produce 
neurotoxic superoxide (62, 63), through the interaction of the NOX complex with 
phosphatidylinositol-3-phosphate (PI3P). Production of PI3P requires activation of RAC2, a 
member of the Ras superfamily of small guanosine triphosphate (GTP)-metabolizing proteins, 
VAV (vav guanine exchange factor) and FCG receptor ligation (64). Among these factors, Tg 
overexpression of Vav1 was indeed lowered by pantethine (Table 1). Thus, the inhibitory 
effect of pantethine on the up-regulation of Cyba, and Vav1 genes in transgenic mice 
supported a reduced activity of the NOX complex and therefore an ongoing decreased 
production of superoxide.  
On the other hand, we found that some of the genes up-regulated in Tg and lowered by 
pantethine (Table 1) are known to be involved in neuroprotection, such as Lyz and Hexb2 
(Fig. 5). For instance, rescuing Hexb expression in Hexb
-/-
 mice, which was detected 
exclusively in microglia (65), reduces neuroinflammation and can attenuate behavioral 
deficits (66).  
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As previously reported (27), we also observed an increased expression of Grn (granulin) in 
Tg that was reduced by pantethine (Table 1). GRNs are a family of secreted peptides 
generated by proteolytic release from progranulin. Interestingly, mutations in the Grn gene 
cause frontotemporal lobar degeneration and may contribute to AD (67).  
Regarding genes of the TGF family, such as Tgfb1 and Tgfbr2, studies in transgenic animal 
models suggest that TGF-β might primarily contribute to AD pathogenesis by influencing Aβ 
production and deposition, resulting in brain microvasculature damage (68). Moreover, TGF-
β was shown to act in synergy with IL-6 to turn on the expression of Gfap (69). In contrast, 
several studies report evidence for neuroprotective features of TGF-1 (70, 71). Indeed, it was 
reported that reduced TGF- signaling leads to neurodegeneration and results in increased 
levels of secreted A (72).  
Overall, these data confirmed an inhibitory effect of pantethine on genes involved in 
inflammation. Thus, reducing inflammation might in turn abrogate its downstream induced 
activities including NO production, phagocytosis and as a consequence the need of 
neuroprotection. However, we cannot exclude that pantethine acts further upstream by 
interfering with A production, which, in the long term, will tune down inflammatory 
processes. Of note, despite the overexpression of inflammatory markers in the 5XFAD mice, 
no changes were observed in our arrays for the expression of pro-inflammatory genes such as 
Il-1 or Tnf-. To validate the transcriptional data, RT-qPCR analyses were performed on 
genes differentially expressed in Tg when compared to WT and the effect of pantethine was 
evaluated. As shown in Fig. 6A, expression of Gfap, Aif1 and Tlr2 was increased in Tg 
compared to WT and this increase was significantly reduced by pantethine treatment in Tg but 
not in WT. Furthermore, while the absence of modulated expression was confirmed for Tnf- 
(Fig. 6A), we observed a significantly higher expression of Il-1 in Tg when compared to WT 
that was decreased by pantethine (Fig. 6B). Such a change in Il-1 expression was also 
confirmed at the protein level (Fig. 6C) with a two-fold increase in Tg compared to WT, an 
increase that was completely abrogated by pantethine. 
 
Pantethine reduces the expression of underexpressed genes in 5XFAD mice involved in 
neurotransmission and A production 
For this analysis, we only considered genes filtered for a threshold ≤0.6 in Tg compared to 
WT animals (Table 2) that were underexpressed in our previous transcriptomic study on 
hippocampi of either 6- or 9-month-old 5XFAD mice (27). Decreased expression of Syn2 
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(synapsin 2) was indeed observed at the earliest clinically detectable stage of AD (73) and 
significantly down-regulated in the hippocampus of the 3xTg-AD mice compared to the WT 
mice (74). It encodes a neuron-specific phosphoprotein involved in the regulation of 
neurotransmitter release and synaptogenesis (Fig. 7) that binds to small synaptic vesicles in 
the presynaptic nerve terminal (75). Noteworthy, as pantethine, ginsenoside Rg1, a drug 
shown to improve behavioral abnormalities in AD, restores its expression in the hippocampus 
of 3xTg-AD mice (74).  
Reduced Gria2 (glutamate ionotropic receptor AMPA type subunit 2) expression was 
observed also at 12 months in the hippocampus in 3xTg-AD mice (76). Its encoded product 
belongs to a family of glutamate receptors, the main excitatory neurotransmitter at many 
synapses in the CNS, and functions as ligand-activated cation channels. It was found that 
Gria2 is subjected to RNA editing, a process shown to be essential for brain function (77), 
and defective Gria2 editing was observed in the hippocampus of AD patients (78).  
Several other selected genes encoded proteins involved in neurotransmission (Fig. 7). DGKG, 
a member of the diacylglycerol kinase family belongs to a class of enzymes that catalyze the 
ATP-dependent conversion of diacylglycerol (DAG1) to phosphatidic acid (PtdOH). It is well 
documented that the coordinated regulation of these two lipid second messengers is 
particularly important in the nervous system where it modulates a variety of neurological 
functions. Indeed, several reports support roles for these enzymes in neuronal spine density, 
myelination, synaptic activity, neuronal plasticity, epileptogenesis and neurotransmitter 
release (reviewed in (79)). Kcnma1 (potassium calcium-activated channel subfamily M alpha 
1) encodes the pore-forming alpha subunit of the MaxiK channels that play a role in neuronal 
excitability (80). NRXN1 (neurexin 1) is a single-pass type 1 membrane protein that binds 
neuroligins to form a Ca
2+
-dependent complex at synapses in the CNS required for 
neurotransmission (81). Heterozygous mutations in NRXN1 were found to impair synaptic 
functions in human neurons (82). Calcium voltage-gated channels such as CACNA2D1 have 
an important role in neurotransmission and genomic aberrations of its gene were found in 
patients with epilepsy and intellectual disability (83).  
In addition, pantethine up-regulation of several genes suggested a possible inhibitory effect of 
pantethine on APP processing and A production (Table 3, Fig. 7), with the exception of 
Grm5 (metabotropic glutamate receptor 5). Indeed, genetic deletion of this gene inhibits A 
production of oligomers and amyloid plaques, thus reducing cognitive impairment and 
pathogenesis in APP/PS1E9, another AD mice model (84). In contrast, restored expression 
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of Apba2, Appbp2 and Gpd2 should decrease A toxicity. Apba2 (amyloid beta precursor 
protein family A member 2) encodes a neuronal adapter protein interacting with APP. This 
interaction stabilizes APP and inhibits production of proteolytic APP fragments including A 
(85-89). Furthermore, it was shown that APBA2-mediated reduction in cerebral A was 
associated with normalization of both cognition and in vivo long-term potentiation in an AD 
transgenic mice model (90). The protein encoded by Appbp2 (Amyloid beta precursor protein 
binding protein 2) interacts with microtubules and is functionally associated with APP 
transport and/or processing (91).  
On the other hand, the restored expression of Gpd2, glycerol-3-phosphate dehydrogenase 2, 
can be related to the effect of pantethine on glycolysis since GPD2 is involved in maintaining 
a high rate of this process (92). Thus, restoring glycolysis, whose impairment was shown to 
promote an increase in A aggregation and internalization (93), might be part of the 
beneficial effect of pantethine. Altogether, these data supported that pantethine maintained the 
constitutive expression of genes underexpressed in Tg to preserve proper CNS functions.  
 
Discussion 
Although the clinical impact of pantethine remains to be proven, we presented here some 
lines of evidence in favor of a beneficial effect of pantethine in AD. Our behavioral test 
suggested that pantethine treatment reduced aggressiveness (Fig. 2). Such an effect was 
supported by the decrease of astrogliosis and microgliosis as well as a reduction of the 
number of amyloid plaques (Fig. 1). While it is well admitted that AD starts with A 
deposition, the precise process that leads to neurodegeneration, is still unknown. A 
aggregation triggers neuroinflammation that is accompanied with an increase of ROS 
production resulting in an oxidative stress. Despite the ability of inflammation to increase 
phagocytosis for A clearance, it is thought that its chronicity can impact negatively the 
protective activities, and restoration of CNS functions cannot be anymore achieved.  
The inhibition of pantethine on Il-1 expression seen in primary cultures of astrocytes upon 
treatment with A oligomers (17) was confirmed in vivo in the present work at both mRNA 
and protein levels (Fig. 6B and C). Such a decrease might suggest a direct effect of the drug 
on the signaling pathway leading to Il-1 expression. For instance, the nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-B) is one of the factors involved in the 
transcriptional induction of cytokines such as Il-1 and IL-1-induced inflammatory genes 
(94). Reduced activity of NF-B by blocking IL-1 signaling was described to alleviate 
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cognitive deficits, attenuate Tau pathology, and partly decrease certain fibrillar and 
oligomeric forms of A (95). At least part of the mechanism leading to Il-1 expression 
requires the translocation of NF-B to the nucleus that can be achieved after binding of A42 
to TLR2. Although the mechanism of action of pantethine is not yet elucidated, it was shown 
that pantethine alters lipid composition and cholesterol content of membrane rafts (96). Such 
an alteration with methyl--cyclodextrin was reported to decrease the levels of nuclear 
translocation of NF-B p65, phosphorylated ERK1/2 and TLR4 (97, 98). It is therefore 
possible that through its effects on lipid rafts as prime subcellular regions where 
amyloidogenic APP processing takes place (99, 100), pantethine affects NF-B activation, 
thus preventing the transcription of inflammatory genes. However, on one hand, 
neuroinflammation and IL-1 contribute to neurodegeneration, a hallmark of AD pathology, 
on the other hand, IL-1 overexpression in a transgenic AD model was reported to trigger 
beneficial effects (101). Indeed, crossing the APP/PS1 AD mouse model with transgenic mice 
that specifically overexpress Il-1 (APP/PS1-IL-1 in the hippocampus led to a reduction of 
amyloid pathology (101). It was suggested that reduced amyloid plaques and therefore the 
beneficial effect of IL-1 resulted from the enhancement of microglial phagocytosis. 
Recently, mapping the immune cell subsets in AD onset and progression (102) led to the 
identification of a potential microglia protective-type associated with neurodegenerative 
diseases (DAM). This subset of cells, which was also detected in post-mortem human brain, is 
characterized by higher expression levels of genes involved in phagocytic and lipid 
metabolism pathways. This DAM activation requires a mechanistically coupled temporal 
event that is initiated in a TREM2-independent pathway, followed by activation of the 
TREM2-dependent program. As suggested in APP/PS1-IL-1 transgenic mice, a beneficial 
role of this DAM population was related to its phagocytic activity that should trigger A 
clearance. However, despite a reduction of plaques, it was shown that neuronal loss induced 
by low concentration of A (not leading to neuronal apoptosis) was mediated by primary 
phagocytosis of neurons by microglia (103). These observations should provide an 
explanation for the failure of therapeutic assays based on A vaccination that did not alleviate 
cognitive deficits (104). We can hypothesize that pantethine through its anti-inflammatory 
effect might hamper the phagocytic activity (illustrated by the reduced expression of Tyrobp 
and Trem2) to a level where healthy neurons are preserved, while formation of amyloid 
plaques is reduced.  
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Although pantethine treatment may be preventive, according to the lipid raft hypothesis, we 
cannot exclude that it acts only in an AD context. Preliminary results (data not shown) on 4-
month-old mice failed to detect any change following pantethine treatment in the expression 
of genes that were modulated in Tg compared to WT. At this time point, neither Aif1, Gfap, 
Cd68, Cd14, Lyz, Cyba, Grn, S100a6, Tyrobp, Trem2 nor genes encoding complement 
factors, whose expression was increased in Tg, were affected by pantethine. Moreover, 
selecting the genes modulated by pantethine in WT did not lead to the identification of 
processes that can be supported by a significant number of genes.  
In addition, another feature that could help understand the beneficial effect of pantethine is 
related to its role in the production of CoA. Inborn errors of CoA biosynthesis have been 
implicated in neurodegeneration with brain iron accumulation (NBIA), a group of rare 
neurodegenerative disorders, suggesting pantethine as suitable treatment for affected 
individuals (105). Moreover, glucose-derived pyruvate is a principal source of acetyl-CoA in 
all brain cells through pyruvate dehydrogenase complex (PDHC) activity. Pantethine could 
therefore compensate the decrease of PDHC activity observed in AD (106) that is responsible 
for cholinergic deficits and loss of cognitive functions.  
On the other hand, it is possible that the effects observed in the 5XFAD result from pantethine 
metabolites. Pantethine can be converted to its monomeric form (pantetheine), which is 
metabolized by pantetheinase to generate pantothenic acid (vitamin B5) and cysteamine, 
known to have direct anti-oxidant effects (107-109). Cysteamine can cross the blood brain 
barrier (110) and was shown to induce the release of BDNF (brain derived-neurotrophic 
factor), inhibiting neuronal loss in Huntington’s disease (111). Cysteamine is highly reactive 
and its oxidation leads to form cystamine. It has been shown that cystamine can activate the 
activity of NRF2, a crucial transcriptional factor involved in the anti-oxidant response both in 
cell cultures and in brain tissue (112). Interestingly, although cystamine inhibits the -
glutamyl synthase that consequently blocks ROS scavenging, it reduces transglutaminase 
activity known to be associated with protein aggregates in AD brain and to trigger A 
oligomerization and aggregation (113). Noteworthy, no side effects of pantethine were 
reported (114, 115). Thus, in case of clear clinical benefits of pantethine treatment, 
determining whether pantethine itself or one of its metabolites is responsible should not be a 
barrier to its use.  
 
Conclusions 
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The present study demonstrated the efficiency of pantethine to reverse AD features such as 
astrogliosis, microgliosis, A deposition and to AD-associated aggressive behavior. These 
changes were accompanied by the reversion of the overexpression of several genes in Tg mice 
related to inflammation/phagocytosis (summarized in figure 8). Since neuroinflammation and 
phagocytosis are crucial events in the course of AD, the various effects of pantethine or one 
of its metabolites (cysteamine, cystamine, pantothenic acid) on these processes are of 
importance. Blocking the signaling pathways that lead to either A deposition, inflammation 
or oxidative stress or the vicious cycle that amplifies these alterations will have several 
downstream consequences that altogether can alleviate AD pathology. It will decrease: i) APP 
processing that will in turn reduce A deposition; ii) the NF-B signaling pathway involved 
in the transcriptional activation of inflammatory genes and in particular those involved in 
phagocytosis such as TREM2. Ultimately, the reduced expression of these genes will impact 
the generation of the highly phagocytic DAM population and consequently might protect 
healthy neurons from phagocytosis and therefore neuronal loss.  
Investigating more deeply the mechanism that sustain the effects of pantethine in 5XFAD 
mice overtime should determine whether pantethine treatment is preventive or curative. In 
addition to test depicting mood changes (i.e., aggressiveness), cognitive evaluations will have 
to be performed in order to provide further confirmation of the beneficial therapeutic effect of 
pantethine treatment. Based on our results, pantethine, provided routinely as a dietary 
supplement, could be considered as a serious therapeutic option for preventing, slowing or 
halting AD progression.  
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Figures, tables, legends  
 
Figure 1: Effects of pantethine on astroglia and microglia reactivity in WT and Tg mice. 
A) Representative epifluorescence microphotographs showing changes in astroglia and 
microglia reactivity with GFAP and Iba1 immunostaining, respectively, and amyloid plaques 
(anti-A 6E10 immunostaining) in the hippocampus (Hc) of untreated or pantethine-treated 
WT and Tg animals, counterstained with nuclear marker Hoechst (blue). Scale bar 100 M. 
Quantification of changes (B) in GFAP, IBA1 immunostaining and (C) number of A 
plaques measured as the immunostained area/total area of the hippocampus. Values are the 
mean ± SEM of three brains (3 slices/brain) per group. *p<0.05; **p<0.01; ***p<0.005 when 
comparing WT+P, Tg and Tg+P groups vs WT, ANOVA followed by post hoc Fisher LSD 
test for (B) and Student t test for (C). 
Figure 2: Effects of pantethine on the aggressive behavior of 5XFAD mice. Quantification 
of the number of attacks (A) and latency to attacks (B) of untreated (Tg, black circles) and 
pantethine-treated (Tg+P, black squares) Tg mice towards WT male mice intruders. Values of 
ten animals are represented as median with interquartile range (done in triplicate with a 
different intruder as described in Materials and Methods). *p<0.05, Mann-Whitney test.  
Figure 3: Effects of pantethine on genes differentially expressed in Tg and WT mice. 
Expression values were filtered for p values <0.05 as provided by Illumina technology. Fold 
changes were deduced from the ratios (Tg+P/Tg, Tg/WT, WT+P/WT) between the four 
different groups and means were calculated. Selecting a fold change ≤0.6 leads to 47 genes 
repressed by pantethine (Gene set 1 in left panel). A similar number of the top pantethine-
induced genes (Gene set 2 in right panel) selected for a fold change ≥1.5 is displayed. All the 
repressed or induced fold changes values are colored in white or in dark gray, respectively 
while unmodulated genes are indicated in light gray.  
Figure 4: Gene distribution in untreated and treated Tg mice. Genes were numbered and 
selected for a fold change ≥1.5 (up-regulated genes) and for a fold change ≤0.6 (down-
regulated genes) indicated by an up and a down arrow, respectively. Only genes with 
expression values exhibiting p values <0.05 as provided by Illumina technology were 
considered.  
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Figure 5: Schematic representation of functional networks involving genes whose 
overexpression in Tg was repressed by pantethine. Table of legends is provided (at the top 
right of the figure). Modulated genes are within a gray box and reduced expression by 
pantethine is indicated by P- in superscript. 
Table 1 : Pantethine reverses the overexpression of genes involved in neuroinflammation 
in Tg. Values represent the ratio of the indicated comparison between groups (three animals 
per group and normalized to WT). p*<0.05; **p<0.01 and ***p<0.005. ANOVA followed by 
post hoc Fisher LSD test.  
Genes Tg/WT Tg+P/Tg Tg+P/WT WT+P/WT 
Aif1 2.5*** 0.6*** 1.5 1 
Cd68 4.5** 0.5** 2.1 0.9 
Tlr2 2.7** 0.6** 1.6 1 
Tlr7 1.9** 0.7* 1.3 1 
Cd14 2.2*** 0.7** 1.4 0.9 
Gfap 5.1** 0.5** 2.6* 1.3 
S100a6 2.8** 0.5** 1.3 1 
Lyz 10** 0.4** 3.7 0.9 
Hexb 3.1** 0.6* 1.9 1.1 
Grn 2.7*** 0.6** 1.5 1 
Tgfb1 3** 0.6* 1.5 1 
Cd63 1.8* 0.5** 0.9 1.1 
Lgals3 1.9* 0.6* 1 1 
 
 
Table 2 : Pantethine reverses the overexpression of genes involved in phagocytosis in Tg. 
Values represent the ratio of the indicated comparison between groups (three animals per 
group and normalized to WT). p*<0.05; **p<0.01 and ***p<0.005. ANOVA followed by 
post hoc Fisher LSD test.  
Genes Tg/WT Tg+P/Tg Tg+P/WT WT+P/WT 
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C1qa 4.8* 0.5* 1.8 1 
C1qb 4.2** 0.5* 2.2 1 
C1qc 4.6** 0.5* 1.9 1 
C4a 6.8*** 0.3*** 2.2 1.3 
C4b 8.1*** 0.3*** 2.8 1.5 
Csf1r 2.7*** 0.6** 1.5* 1.1 
Trem2 9.5*** 0.4*** 3.4 1.2 
Tyrobp 6*** 0.4*** 2.5* 1 
Cyba 3.9*** 0.5*** 1.7 0.9 
Vav1 2.4**** 0.7** 1.6* 1.1 
 
Figure 6: Expression analyses of inflammatory genes. RT-qPCR analyses of inflammatory 
genes Gfap, Aif1, Csf1r, Tlr2, Cyba and Tnf- (A) and Il-1 (B). Values are the mean ± SEM 
of three mice per group normalized to WT. (C) Quantification of IL-1 levels in the 
hippocampus by ELISA. Values are the mean ± SEM of three mice per group. *p<0.05; 
**p<0.01; ***p<0.005 when comparing WT+P, Tg and Tg+P groups vs WT, ANOVA 
followed by post hoc Fisher LSD test. 
 
Table 3: Down-regulated genes in Tg whose expression was reversed by pantethine. 
Values represent the ratio of the indicated comparison between groups (three animals per 
group and normalized to WT). p*<0.05; **p<0.01 and ***p<0.005. ANOVA followed by 
post hoc Fisher LSD test.  
Genes Tg/WT Tg+P/Tg Tg+P/WT WT+P/WT 
Syn2 0.3*** 3.1*** 0.9 0.9 
Gria2 0.5*** 2.1** 1 1.3 
Apba2 0.5* 2* 1.1 1 
Appbp2 0.5*** 1.7** 0.7* 0.8 
Grm5 0.3** 3.7** 0.9 1 
Gpd2 0.4*** 2.2** 0.9 0.9 
Dgkg 0.5** 1.8** 0.9 0.9 
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Kcnma1 0.4*** 2.1** 0.8 0.8 
Nrxn1 0.5* 2** 0.9 1 
Cacna2d1 0.5* 2.5** 1.1 1.2 
 
Figure 7: Schematic representation of functional networks involving genes whose down-
regulation in Tg was reversed by pantethine. Table of legends is indicated in Figure 6. 
Modulated genes are within a gray box and induced expression by pantethine is indicated by 
P+ in superscript. 
Figure 8: Schematic representation of pantethine inhibitory activity (P in red) in AD as 
evidenced in this study. P followed by a question mark (?) means that the activity remains to 
be demonstrated. P with + or – in superscript indicates either an up-regulation or a down-
regulation of the genes in Tg in response to pantethine treatment, respectively, when 
compared to untreated Tg. 
 
